<document xmlns="http://cnx.rice.edu/cnxml">
  <title>Cardiac Emergency Drugs</title>
  <metadata xmlns:md="http://cnx.rice.edu/mdml">
    <md:title>Cardiac Emergency Drugs</md:title>
    <md:content-id>m00389</md:content-id>
    <md:uuid>90182f31-d039-45bb-89eb-d084a948d9c2</md:uuid>
  </metadata>
  <content>
<section class="learning-objectives" id="sect-00001">
<title>Learning Outcomes</title>
<para id="para-00001">By the end of this section, you should be able to:</para>
<list id="list-00001">
<item>Identify the characteristics of drugs used to treat cardiac emergencies.</item>
<item>Explain the indications, actions, adverse reactions, and interactions of drugs used to treat cardiac emergencies.</item>
<item>Describe nursing implications of drugs used to treat cardiac emergencies.</item>
<item>Explain the client education related to drugs used to treat cardiac emergencies.</item>
</list>
</section>
<para id="para-00002">The goal of treatment for a client with AMI or unstable angina is restoring the blood supply to the affected area of the heart muscle. Drugs can help either supply more oxygen to the heart (temporarily) or reduce the heart’s demand for oxygen. If there is stenosis (narrowing) in a coronary artery, the definitive treatment is having the client undergo stent placement or, if stenting is not an option, coronary artery bypass grafting. It is very important that this treatment not be delayed because it can save heart tissue. Thrombolytic therapy may also be used to dissolve an occlusive clot that is causing the coronary ischemia or infarction. Thrombolytic therapy is discussed in <link document="m00318">Anticoagulant, Antiplatelet, and Thrombolytic Drugs</link>.</para>
<section id="sect-00003">
<title>Acute Myocardial Infarction and Unstable Angina Drugs</title>
<para id="para-00003">Four classifications of drugs may be used in emergency situations for AMI and unstable angina: aspirin, oxygen, nitroglycerin, and, occasionally, morphine. In either AMI or unstable angina, the most important thing to consider is blood supply to the heart. If the cardiac cells are not receiving blood, they will become ischemic and eventually will die. Each of the medications is used to enhance oxygen-rich blood flow to the heart.</para>
<section id="sect-00004">
<title>Aspirin</title>
<para id="para-00004"><term class="no-emphasis" id="term-00001">Salicylic acid</term> (<term class="no-emphasis" id="term-00002">aspirin</term>) has been used for mild pain relief for more than 100 years. (<link document="m00309">Pain Response Drugs</link> discusses aspirin as a nonopioid analgesic.) It was also found to work as an antiplatelet drug; therefore, it is useful in suspected AMI and unstable angina. Aspirin irreversibly binds to receptors on platelets, which prevents them from sticking to other platelets. Because platelet aggregation is the first step in blood clotting, if this can be reduced, then the heart may receive more blood.</para>
<section id="sect-00005">
<title>Adverse Effects and Contraindications</title>
<para id="para-00005">Aspirin can cause gastritis and bleeding in the stomach, other parts of the gastrointestinal tract, brain, and spinal cord.</para>
<para id="para-00006">Contraindications to aspirin are allergy to nonsteroidal anti-inflammatory drugs (NSAIDs), asthma, hemophilia, and other blood clotting disorders. Pediatric clients who have suspected viral illnesses should not take aspirin because Reye’s syndrome, a potentially fatal complication, could develop. As a precaution, aspirin is generally not used in <term class="no-emphasis" id="term-00003">pediatric clients</term>.</para>
<para id="para-00007"><link target-id="table-00001" document="m00389"/> is a drug prototype table for aspirin used in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00001">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Class</emphasis></span><newline/>
Salicylic acid<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Mechanism of Action</emphasis></span><newline/>
Irreversibly binds with receptors on platelets, which makes them unable to bind with other platelets</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Dosage</emphasis></span><newline/>
<emphasis effect="italics">For acute myocardial infarction or unstable angina:</emphasis> 325 mg orally (chewed) once. (If client is unable to take orally, administer rectal suppository form.)</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Indications</emphasis></span><newline/>
Mild pain <newline/>
Platelet inhibition in suspected AMI or unstable angina<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Therapeutic Effects</emphasis></span><newline/>
Platelet inhibition<newline/>
Relief of mild pain</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Interactions</emphasis></span><newline/>
Anticoagulants<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Food Interactions</emphasis></span><newline/>
Alcohol <newline/>
Tobacco</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Adverse Effects</emphasis></span><newline/>
Gastrointestinal upset/gastritis<newline/>
Gastrointestinal bleeding</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Contraindications</emphasis></span><newline/>
Allergy to NSAIDs<newline/>
Asthma<newline/>
Hemophilia<newline/>
Pediatric clients (risk of developing Reye’s syndrome)</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Aspirin</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00006">
<title>Nursing Implications</title>
<para id="para-00008">The nurse should do the following for clients who are taking aspirin:</para>
<list list-type="bulleted" id="list-00002">
<item>Assess the client’s allergies and verify that they are not allergic to any of the NSAIDs.</item>
<item>Assess for signs and symptoms of bleeding.</item>
<item>In the event of suspected AMI or unstable angina, direct the client to chew the aspirin and then swallow it.</item>
<item>Provide client teaching regarding the drug. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00001">
<para id="para-00009"><emphasis effect="bold">The client taking aspirin in an emergency situation should:</emphasis></para>
<list list-type="bulleted" id="list-00003">
<item>Inform the health care team if they have an allergy to aspirin or other NSAIDs or have a diagnosis of asthma.</item>
<item>Chew the aspirin tablet before swallowing.</item>
</list>
<para id="para-00010">See <link document="m00318">Anticoagulant, Antiplatelet, and Thrombolytic Drugs</link> for full client teaching guidelines on the use of aspirin in nonemergency situations.</para>
</note>
<note class="black-box" id="note-00002">
<para id="para-00011"><emphasis effect="bold">Aspirin</emphasis></para>
<para id="para-00012">The risk of serious bleeding in the stomach, gastrointestinal tract, brain, and spinal cord is increased with aspirin and other <term class="no-emphasis" id="term-00004">NSAIDs</term>.</para>
<para id="para-00013">Concomitant use of aspirin greater than 100 mg per day can reduce the efficacy of ticagrelor (an antiplatelet medication) and should be avoided.</para>
</note>
</section>
</section>
<section id="sect-00007">
<title>Oxygen</title>
<para id="para-00014">In an AMI or unstable angina, the cardiac cells are deprived of <term class="no-emphasis" id="term-00005">oxygen</term>. When cells are deprived of oxygen, they eventually will die. <term class="no-emphasis" id="term-00006">Supplemental oxygen</term> may be used if the client’s <term id="term-00007">oxygen saturation</term> is less than 94% on room air. In the past, oxygen was used immediately for clients with suspected AMI or unstable angina; however, it was not found to be beneficial if used in clients who were already maintaining an oxygen saturation of 95% or more (Hofmann et al., 2017). Oxygen is typically delivered via nasal cannula starting at 2 L/min and can be titrated to 6 L/min. If the client requires a higher dose to maintain oxygen saturation greater than 94%, then other methods of oxygen delivery should be used.</para>
</section>
<section id="sect-00008">
<title>Nitroglycerin</title>
<para id="para-00015"><term class="no-emphasis" id="term-00008">Nitroglycerin</term> is a <term id="term-00009">nitrate</term> and a first-line treatment for clients with AMI or unstable angina. Nitroglycerin is converted to nitrous oxide, which ultimately causes smooth muscles around arteries to relax. Smooth muscle relaxation causes vasodilation. In AMI or unstable angina, the cardiac myocytes are not receiving enough oxygen, and vasodilation allows more oxygen to be delivered to hypoxic cells. In emergency situations, nitroglycerin is administered either sublingually or intravenously.</para>
<para id="para-00016"><link document="m00313">Antihypertensive and Antianginal Drugs</link> discusses nitrates more extensively.</para>
<section id="sect-00009">
<title>Adverse Effects and Contraindications</title>
<para id="para-00017">Adverse effects include orthostatic hypotension, tachycardia, paradoxical bradycardia, flushing, peripheral edema, nausea and vomiting, headache, and blurred vision.</para>
<para id="para-00018">Contraindications include allergies to nitrates, concomitant use of phosphodiesterase (PDE) inhibitors such as tadalafil and sildenafil, history of right ventricular infarction, and hypertrophic cardiomyopathy.</para>
<para id="para-00019">Nitrates should be used cautiously in clients who are on chronic diuretic therapy, have low systolic blood pressure, have autonomic nervous system dysregulation, or are pregnant or breastfeeding.</para>
<note class="safety-alert" id="note-00003">
<title>Nitroglycerin</title>
<para id="para-00021">Nitrates can cause hypotension. In an emergency situation, make sure the client is sitting or lying down before administering nitroglycerin.</para>
</note>
<para id="para-00022"><link target-id="table-00002" document="m00389"/> is a drug prototype table for nitroglycerin use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00002">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Class</emphasis></span><newline/>
Nitrate<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Mechanism of Action</emphasis></span><newline/>
Converts to nitric oxide, which ultimately causes smooth muscle relaxation and vasodilation</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Dosage</emphasis></span><newline/>
<emphasis effect="italics">For acute myocardial infarction or unstable angina:</emphasis> <newline/>
<emphasis effect="italics">Sublingual:</emphasis> 0.15–0.6 mg as needed for chest pain every 5 min up to 3 times.<newline/>
<emphasis effect="italics">Intravenous (IV):</emphasis> 5–10 mcg/min up to 100 mcg/min.</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Indications</emphasis></span><newline/>
For acute relief of pain in suspected acute myocardial infarction or unstable angina<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Therapeutic Effects</emphasis></span><newline/>
Relieves pain <newline/>
Increases delivery of oxygen to cardiac tissue</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Interactions</emphasis></span><newline/>
Avanafil <newline/>
Riociguat<newline/>
Sildenafil<newline/>
Tadalafil<newline/>
Vardenafil<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Food Interactions</emphasis></span><newline/>
Alcohol <newline/>
Tobacco</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Adverse Effects</emphasis></span><newline/>
Orthostatic hypotension<newline/>
Tachycardia<newline/>
Paradoxical bradycardia<newline/>
Flushing<newline/>
Peripheral edema<newline/>
Nausea and vomiting<newline/>
Headache<newline/>
Blurred vision</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Contraindications</emphasis></span><newline/>
Allergy to nitrates<newline/>
Hypersensitivity<newline/>
Increased intracranial pressure<newline/>
Cardiomyopathy<newline/>
History of right ventricular infarction <newline/>
Shock<newline count="2"/>
Caution:<newline/>
Chronic diuretic therapy<newline/>
Low systolic blood pressure<newline/>
Autonomic system dysregulation<newline/>
Pregnancy<newline/>
Lactation</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Nitroglycerin</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00010">
<title>Nursing Implications</title>
<para id="para-00023">Refer to <link document="m00313">Antihypertensive and Antianginal Drugs</link> for a full list of nursing implications for clients prescribed nitrates. In the event of suspected AMI or unstable angina, the health care provider may order sublingual nitroglycerin until an IV line is in place. If the client is receiving IV nitroglycerin, the nurse will receive orders to titrate the nitroglycerin based on pain level and blood pressure.</para>
<para id="para-00024">The nurse should do the following for clients who are receiving nitroglycerin intravenously for chest pain:</para>
<list list-type="bulleted" id="list-00004">
<item>Place the client on continuous cardiac monitoring.</item>
<item>Monitor vital signs frequently, particularly blood pressure, because nitroglycerin can cause significant hypotension.</item>
<item>If symptomatic hypotension occurs, do not give the nitroglycerin and inform the health care provider.</item>
<item>Frequently assess pain level.</item>
<item>Assess for headache and give pain medication for it as ordered.</item>
<item>Provide client teaching regarding the drug. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00004">
<para id="para-00025"><emphasis effect="bold">The client receiving nitroglycerin for unstable angina or AMI should:</emphasis></para>
<list list-type="bulleted" id="list-00005">
<item>Alert the nurse if any of these occur:
<list list-type="bulleted" id="list-00006">
<item>Their chest pain changes (either improves or worsens)</item>
<item>They feel faint</item>
<item>They experience nausea or vomiting</item>
</list></item></list>
<para id="para-00026">See <link document="m00313">Antihypertensive and Antianginal Drugs</link> for full client teaching guidelines on nitroglycerin, including client home usage.</para>
</note>
</section>
</section>
<section id="sect-00011">
<title>Morphine</title>
<para id="para-00027"><term class="no-emphasis" id="term-00010">Morphine</term> is a potent, fast-acting <term id="term-00011">opioid agonist</term>. It binds to opioid receptors in the central and peripheral nervous systems to modulate (decrease) the pain response. Morphine also can help relieve anxiety, which may lower heart rate and reduce the heart’s demand for oxygen. For many years, morphine was a first-line drug in the emergency management of AMI and unstable angina, but now it is used if nitroglycerin cannot control the chest pain (Hermiz &amp; Sedhai, 2023). <link document="m00309">Pain Response Drugs</link> covers opioid agonists in depth.</para>
<section id="sect-00012">
<title>Adverse Effects and Contraindications</title>
<para id="para-00028">Opioids must be managed carefully due to their potential adverse effects, which include respiratory depression, respiratory arrest, apnea, circulatory depression, shock, cardiac arrest, sedation, lightheadedness, dizziness, nausea, vomiting, and constipation.</para>
<para id="para-00029">Opioids should not be used if the client has a known hypersensitivity to morphine, respiratory depression, acute or severe asthma, hypercarbia, or a paralytic ileus.</para>
<note class="safety-alert" id="note-00005">
<title><term class="no-emphasis" id="term-00012">Opioid Analgesics</term></title>
<para id="para-00031">Morphine can cause respiratory depression, respiratory arrest, cardiac arrest, and shock. Nurses must monitor the client frequently (reassess at least every 5–10 minutes) when using morphine to control pain.</para>
</note>
<para id="para-00032"><link target-id="table-00003" document="m00389"/> is a drug prototype table for opioid agonists featuring morphine. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00003">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Class</emphasis></span><newline/>
Opioid agonist<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Mechanism of Action</emphasis></span><newline/>
Primarily a mu opioid receptor agonist that causes modulation of pain in the central and peripheral nervous systems</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Dosage</emphasis></span><newline/>
<emphasis effect="italics">For acute myocardial infarction if optimal nitroglycerin does not control chest pain:</emphasis> 4–8 mg IV initially, then 2–8 mg IV repeated every 5–15 minutes if needed for complete pain relief.</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Indications</emphasis></span><newline/>
For management of pain not responsive to nonnarcotic analgesics<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Therapeutic Effects</emphasis></span><newline/>
Relieves pain</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Interactions</emphasis></span><newline/>
Central nervous system depressants:<newline/>
<list list-type="bulleted" id="list-00007">
<item>Other narcotic analgesics</item>
<item>Phenothiazines</item>
<item>Tricyclic antidepressants</item>
<item>Tranquilizers</item>
<item>Sedatives</item>
<item>Hypnotics</item>
<item>Antiemetics</item>
</list>
Muscle relaxants<newline/>
Cimetidine<newline/>
Anticholinergics<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Food Interactions</emphasis></span><newline/>
Alcohol</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Adverse Effects</emphasis></span><newline/>
Respiratory depression<newline/>
Respiratory arrest<newline/>
Apnea <newline/>
Circulatory depression<newline/>
Shock<newline/>
Cardiac arrest<newline/>
Sedation<newline/>
Lightheadedness<newline/>
Dizziness<newline/>
Nausea<newline/>
Vomiting<newline/>
Constipation</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Contraindications</emphasis></span><newline/>
Known hypersensitivity to morphine<newline/>
Respiratory depression<newline/>
Acute or severe bronchial asthma or hypercarbia<newline/>
Paralytic ileus</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Morphine</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00013">
<title>Nursing Implications</title>
<para id="para-00033">The nurse should do the following for clients who are receiving morphine for chest pain:</para>
<list list-type="bulleted" id="list-00008">
<item>Place the client on continuous cardiac monitoring.</item>
<item>Assess the client’s vital signs and level of consciousness before administering morphine intravenously.</item>
<item>Reassess vital signs and level of consciousness frequently after administering morphine intravenously.</item>
<item>If the client’s respiratory rate is less than 10 breaths/min, inform the health care provider.</item>
<item>Assess the client’s pain frequently.</item>
<item>Reassess the client’s pain 15 minutes after administering morphine.</item>
<item>Ensure that a morphine reversal agent (naloxone) is available.</item>
<item>Provide client teaching regarding the drug. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00006">
<para id="para-00034"><emphasis effect="bold">The client receiving morphine for unstable angina or AMI should:</emphasis></para>
<list list-type="bulleted" id="list-00009">
<item>Alert the nurse if any of these occur:
<list list-type="bulleted" id="list-00010">
<item>Their chest pain changes (either improves or worsens)</item>
<item>They feel sleepy, dizzy, or lightheaded</item>
<item>They experience nausea or vomiting</item></list>
</item></list>
<para id="para-00035">See <link document="m00309">Pain Response Drugs</link> for full client teaching guidelines on morphine.</para>
</note>
<note class="black-box" id="note-00007">
<para id="para-00036"><emphasis effect="bold">Morphine</emphasis></para>
<para id="para-00037">Life-threatening respiratory depression, addiction, abuse, and misuse can occur with morphine use. Concomitant use of morphine with benzodiazepines or other central nervous system depressants may result in profound sedation and/or respiratory depression.</para>
</note>
</section>
</section>
</section>
<section id="sect-00014">
<title>Dysrhythmia Drugs</title>
<para id="para-00038">There is a saying in cardiac nursing that there are only three problems with the conduction system: The heart can beat too fast, too slow, or not at all.</para>
<para id="para-00039">This is an oversimplification, but each one of these problems can lead to hemodynamic instability and potentially death. Once again, the importance of cardiac output cannot be emphasized enough. Cardiac output is a function of heart rate and stroke volume. If the heart rate is too fast, then ventricular filling cannot occur, and cardiac output is affected. If the heart rate is too slow, then not enough blood will be pumped, and cardiac output is affected. If there is no heart rate at all, then, of course, there is no cardiac output.</para>
<para id="para-00040">The cardiac conduction system—specifically, the SA node—determines the heart rate. The SA node is influenced by the sympathetic and parasympathetic nervous systems. As with all other tissues in the body, it must have a blood supply, and it needs the correct amount of electrolytes (sodium, potassium, calcium, and chloride) to function optimally. The cardiac conduction system (see <link target-id="fig-00003" document="m00388"/>) includes the SA node, the AV node, the bundle of His, and the Purkinje fibers.</para>
<para id="para-00041">Although the main pacemaker of the heart is the SA node, other areas of the conduction system generate electrical impulses. The SA node generates impulses at 60–100 beats/min, the AV node at 40–60 beats/min, and the ventricles at 20–40 beats/min. Typically, the conduction system will conduct the fastest rate, which is why the system normally follows the SA node impulses.</para>
<para id="para-00042">Cardiac conduction can be categorized by area of the heart: atrial conduction and ventricular conduction. Most conduction problems in the atria are not life-threatening, but supraventricular tachycardia, atrial fibrillation with rapid ventricular response, and sick sinus syndrome (which can cause hemodynamically unstable bradycardia) can cause hemodynamic instability and potentially death. Ventricular dysrhythmias nearly always cause hemodynamic instability and will lead to death if not treated rapidly. Ventricular dysrhythmias include ventricular tachycardia, pulseless ventricular tachycardia, and ventricular fibrillation.</para>
<para id="para-00043">Emergency dysrhythmias discussed in this chapter include:</para>
<list list-type="bulleted" id="list-00011">
<item><term id="term-00013">Asystole</term>: Complete cessation of electrical activity in the heart</item>
<item><term id="term-00014">Atrial fibrillation with rapid ventricular response</term>: Rapid electrical stimulation and conduction that cause the atria to have unorganized contraction (fibrillation) and the ventricles to beat rapidly</item>
<item><term id="term-00015">Symptomatic bradycardia</term>: Heart rate less than 60 beats per minute that negatively affects cardiac output</item>
<item><term id="term-00016">Pulseless electrical activity</term>: Life-threatening dysrhythmia in which the electrical system conducts impulses but the cardiac myocytes do not respond</item>
<item><term id="term-00017">Pulseless ventricular tachycardia</term>: Life-threatening dysrhythmia in which the ventricles contract so rapidly that a pulse cannot be detected</item>
<item><term id="term-00018">Supraventricular tachycardia</term>: Rapid heart rate that originates from above the ventricles</item>
<item><term id="term-00019">Ventricular fibrillation</term>: Life-threatening dysrhythmia originating in the ventricles in which ventricles are not coordinated in their contraction, leading to minimal cardiac output</item>
<item><term id="term-00020">Ventricular tachycardia</term>: Dysrhythmia that originates from the ventricles and causes them to contract rapidly; if it becomes fast enough, it can turn into pulseless ventricular tachycardia, which is life-threatening</item>
</list>
<para id="para-00044">The drugs described in this section are used in emergency situations to restore hemodynamic stability and improve cardiac conduction. Antiarrhythmic drugs that are used long term are discussed in <link document="m00312">Antidysrhythmic Drugs</link>.</para>
<section id="sect-00015">
<title>Adenosine</title>
<para id="para-00045"><term class="no-emphasis" id="term-00021">Adenosine</term> is a <term class="no-emphasis" id="term-00022">class V antidysrhythmic</term> drug. It is used to convert supraventricular tachycardia into normal sinus rhythm (the regular conduction pattern of the heart). Adenosine affects how potassium and calcium move into and out of the myocardial conduction cells that affect the resting membrane potential, causing conduction to take longer. This is useful in disrupting supraventricular tachycardia and gives the heart the opportunity to restart in normal sinus rhythm.</para>
<section id="sect-00016">
<title>Adverse Effects and Contraindications</title>
<para id="para-00046">Adenosine may cause flushing of the skin, palpitations, chest pain, hypotension, lightheadedness, nausea, sweating, nervousness, numbness, and apprehension. It decreases conduction through the AV node and may produce short-lasting heart block. It is important to note that the benefit of adenosine in a life-threatening event outweighs the risk of adverse effects.</para>
<para id="para-00047">Contraindications to adenosine include second- or third-degree heart block (except in clients with a pacemaker), sinus node disease (sick sinus syndrome or symptomatic bradycardia), and known hypersensitivity to adenosine.</para>
<para id="para-00048"><link target-id="table-00004" document="m00389"/> is a drug prototype table for adenosine use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00004">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Class</emphasis></span><newline/>
Class V <term class="no-emphasis" id="term-00023">antiarrhythmic</term><newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Mechanism of Action</emphasis></span><newline/>
Affects potassium and calcium channels in the myocardial conducting cells, significantly slowing heart rate</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Dosage</emphasis></span><newline/>
<emphasis effect="italics">For supraventricular tachycardia:</emphasis> 6 mg rapid IV bolus (administered over 1–2 seconds); if supraventricular tachycardia is not eliminated, administer 12 mg rapid IV bolus. The 12 mg dose may be repeated once if required.</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Indications</emphasis></span><newline/>
To convert supraventricular tachycardia to normal sinus rhythm<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Therapeutic Effects</emphasis></span><newline/>
Slows nerve impulses in the heart</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Interactions</emphasis></span><newline/>
Methylxanthines (caffeine, theophylline) <newline/>
Dipyridamole<newline/>
Carbamazepine<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Food Interactions</emphasis></span><newline/>
Caffeine</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Adverse Effects</emphasis></span><newline/>
Flushing of skin<newline/>
Palpitations<newline/>
Chest pain<newline/>
Hypotension <newline/>
Lightheadedness<newline/>
Nausea<newline/>
Sweating<newline/>
Nervousness<newline/>
Numbness<newline/>
Apprehension<newline/>
Short-lasting heart block due to decreased conduction through the AV node</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Contraindications</emphasis></span><newline/>
Second- or third-degree heart block (except in clients with a pacemaker) <newline/>
Sinus node disease (sick sinus syndrome or symptomatic bradycardia) <newline/>
Known hypersensitivity to adenosine</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Adenosine</emphasis> (sources: https://dailymed.nlm.nih.gov/dailymed/; Singh &amp; McKintosh, 2022)</caption>
</table>
<note class="clinical-tip" id="note-00008">
<title>Adenosine</title>
<para id="para-00050">Adenosine has a very short half-life and should be administered as a rapid IV bolus directly into a vein, followed by a rapid saline flush.</para>
</note>
</section>
<section id="sect-00017">
<title>Nursing Implications</title>
<para id="para-00051">The nurse should do the following for clients who are receiving adenosine intravenously:</para>
<list list-type="bulleted" id="list-00012">
<item>Place the client on continuous cardiac monitoring.</item>
<item>Monitor vital signs frequently.</item>
<item>Administer adenosine as an IV push directly into a vein over 1–2 seconds.</item>
<item>Administer a rapid saline bolus immediately after administering adenosine.</item>
<item>Be prepared to administer a second dose.</item>
<item>If the client is alert, inform them that they may feel chest pain once the bolus is given. The chest pain should subside quickly (in less than 1 minute).</item>
<item>Provide client teaching regarding the drug. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00009">
<para id="para-00052">In supraventricular tachycardia, the client may not be conscious because of decreased cardiac output.</para>
<para id="para-00053"><emphasis effect="bold">If alert and oriented, the client receiving adenosine should:</emphasis></para>
<list list-type="bulleted" id="list-00013">
<item>Inform the health care team if they have a known heart block or sick sinus syndrome.</item>
</list>
</note>
</section>
</section>
<section id="sect-00018">
<title>Amiodarone</title>
<para id="para-00054"><term class="no-emphasis" id="term-00024">Amiodarone</term> is a <term class="no-emphasis" id="term-00025">class III antiarrhythmic</term> drug used for hemodynamically unstable ventricular tachycardia, ventricular fibrillation, and other dysrhythmias. It blocks potassium and calcium channels from opening, which slows down cardiac conduction and therefore slows heart rate. <link document="m00312">Antidysrhythmic Drugs</link> covers the use of amiodarone in the management of chronic dysrhythmias.</para>
<section id="sect-00019">
<title>Adverse Effects and Contraindications</title>
<para id="para-00055">Amiodarone can cause hypotension, bradycardia, atrioventricular block, hepatic injury, heart rhythm disturbances, pulmonary injury, loss of vision, thyroid injury, hypersensitivity, anorexia, nausea, vomiting, and photosensitivity. It is important to note that the benefit of amiodarone in a life-threatening event outweighs the risk of adverse effects.</para>
<para id="para-00056">Contraindications to amiodarone include known hypersensitivity, cardiogenic shock, marked sinus bradycardia, and second- or third-degree AV block (unless the client has an implanted pacemaker).</para>
<para id="para-00057"><link target-id="table-00005" document="m00389"/> is a drug prototype table for amiodarone use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00005">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Class</emphasis></span><newline/>
Class III antiarrhythmic<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Mechanism of Action</emphasis></span><newline/>
Blocks potassium and calcium channels in the cardiac conducting cells, slowing the heart rate</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Dosage</emphasis></span><newline/>
<emphasis effect="italics">For hemodynamically unstable ventricular tachycardia or ventricular fibrillation:</emphasis> 150 mg IV bolus given over 10 minutes, then 360 mg IV infused over the next 6 hours, then 540 mg IV infused over the next 18 hours; dosage should be titrated after 24 hours.</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Indications</emphasis></span><newline/>
For ventricular fibrillation and hemodynamically unstable ventricular tachycardia<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Therapeutic Effects</emphasis></span><newline/>
Slows nerve impulses in the heart</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Interactions</emphasis></span><newline/>
Drugs that prolong the QT interval (increased risk of torsade de pointes):<newline/>
<list list-type="bulleted" id="list-00014">
<item>Class I antiarrhythmics</item>
<item>Class III antiarrhythmics</item>
<item>Lithium</item>
<item>Phenothiazines</item>
<item>Tricyclic antidepressants</item>
</list>
Digoxin (increases effect)<newline/>
Warfarin (increases effect)<newline/>
HMG-CoA reductase inhibitors/statin drugs (increases effect; risk of myopathy)<newline/>
Protease inhibitors<newline/>
St. John’s wort<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Food Interactions</emphasis></span><newline/>
Grapefruit/grapefruit juice</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Adverse Effects</emphasis></span><newline/>
Anorexia <newline/>
Nausea and vomiting<newline/>
Hypotension<newline/>
Bradycardia and atrioventricular block<newline/>
Hepatic injury<newline/>
Dysrhythmias<newline/>
Photosensitivity <newline/>
Pulmonary injury<newline/>
Loss of vision<newline/>
Thyroid injury<newline/>
Hypersensitivity</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Contraindications</emphasis></span><newline/>
Known hypersensitivity<newline/>
Cardiogenic shock<newline/>
Marked sinus bradycardia<newline/>
Second- or third-degree AV block (unless the client has an implanted pacemaker)</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Amiodarone</emphasis> (sources: https://dailymed.nlm.nih.gov/dailymed/; Florek &amp; Girsadas, 2022)</caption>
</table>
<note class="safety-alert" id="note-00010">
<title>Amiodarone</title>
<para id="para-00059">Amiodarone can cause pulmonary toxicity and swelling in the lungs.</para>
</note>
</section>
<section id="sect-00020">
<title>Nursing Implications</title>
<para id="para-00060">The nurse should do the following for clients who are receiving amiodarone intravenously:</para>
<list list-type="bulleted" id="list-00015">
<item>Place the client on continuous cardiac monitoring.</item>
<item>Monitor vital signs frequently.</item>
<item>Monitor level of consciousness.</item>
<item>Monitor laboratory values and report abnormal findings to the health care provider.</item>
<item>Have resuscitative equipment and drugs immediately available.</item>
<item>Monitor for adverse effects of amiodarone infusion.</item>
<item>Provide client teaching regarding the drug. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00011">
<para id="para-00061"><emphasis effect="bold">The client receiving amiodarone should:</emphasis></para>
<list list-type="bulleted" id="list-00016">
<item>Inform the health care provider of nausea, which may be an early indication of liver damage.</item>
</list>
</note>
<para id="para-00062">Clients with ventricular fibrillation or hemodynamically unstable ventricular tachycardia are typically no longer conscious. See <link document="m00312">Antidysrhythmic Drugs</link> for client teaching guidelines for amiodarone in less acute situations.</para>
<note class="black-box" id="note-00012">
<para id="para-00063"><emphasis effect="bold">Amiodarone</emphasis></para>
<para id="para-00064">Amiodarone can cause pulmonary toxicity and swelling in the lungs.</para>
</note>
</section>
</section>
<section id="sect-00021">
<title>Atropine</title>
<para id="para-00065"><term class="no-emphasis" id="term-00026">Atropine</term> is a first-line drug used for treating symptomatic bradycardia. It is an <term id="term-00027">anticholinergic</term> drug, which means it blocks receptors in the parasympathetic nervous system. The heart is constantly stimulated by both the parasympathetic nervous system (PNS) and the sympathetic nervous system (SNS). It reacts to whichever system is sending more impulses. If the PNS signals are blocked, then the heart receives fewer signals from acetylcholine, the primary neurotransmitter of the PNS. Because of fewer signals from the PNS, the SNS signaling is stronger, which increases the heart rate.</para>
<section id="sect-00022">
<title>Adverse Effects and Contraindications</title>
<para id="para-00066">Atropine can cause tachycardia, acute glaucoma, pyloric obstruction, and complete urinary retention. It is important to note that the benefit of atropine in a life-threatening event outweighs the risk of adverse effects.</para>
<para id="para-00067">There are no contraindications to the use of atropine.</para>
<para id="para-00068"><link target-id="table-00006" document="m00389"/> is a drug prototype table for atropine use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00006">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Class</emphasis></span><newline/>
Anticholinergic<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Mechanism of Action</emphasis></span><newline/>
Inhibits cholinergic nerves, resulting in decreased parasympathetic stimulation</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Dosage</emphasis></span><newline/>
<emphasis effect="italics">For symptomatic bradycardia:</emphasis> 1 mg IV every 3–5 minutes; maximum dose: 3 mg.</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Indications</emphasis></span><newline/>
Symptomatic bradycardia<newline/>
Treatment of organophosphorus poisoning <newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Therapeutic Effects</emphasis></span><newline/>
Increased heart rate</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Interactions</emphasis></span><newline/>
Mexiletine<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Food Interactions</emphasis></span><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Adverse Effects</emphasis></span><newline/>
Tachycardia <newline/>
Acute glaucoma<newline/>
Pyloric obstruction<newline/>
Complete urinary retention</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Contraindications</emphasis></span><newline/>
None</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Atropine</emphasis> (sources: https://dailymed.nlm.nih.gov/dailymed/; McLendon &amp; Preuss, 2022)</caption>
</table>
</section>
<section id="sect-00023">
<title>Nursing Implications</title>
<para id="para-00069">The nurse should do the following for clients receiving atropine intravenously:</para>
<list list-type="bulleted" id="list-00017">
<item>Place the client on continuous cardiac monitoring.</item>
<item>Monitor vital signs frequently.</item>
<item>Monitor level of consciousness.</item>
<item>Have resuscitative equipment and drugs available.</item>
<item>Provide client teaching regarding the drug. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00013">
<para id="para-00070">In symptomatic bradycardia, the client may not be conscious because of decreased cardiac output.</para>
<para id="para-00071"><emphasis effect="bold">If alert and oriented, the client receiving atropine should:</emphasis></para>
<list list-type="bulleted" id="list-00018">
<item>Inform the health care team if they feel different (better or worse) after the initial dose.</item>
<item>Inform the health care team if they feel a fast heart rate or racing heart after the dose.</item>
</list>
</note>
</section>
</section>
<section id="sect-00024">
<title>Diltiazem</title>
<para id="para-00072"><term class="no-emphasis" id="term-00028">Diltiazem</term> is a nondihydropyridine <term id="term-00029">Calcium channel blocker</term> and a <term class="no-emphasis" id="term-00030">class IV antiarrhythmic</term> drug. Nondihydropyridine calcium channel blockers inhibit calcium flow into cardiac myocytes, which results in decreased force of contractions and decreased heart rate. Therefore, diltiazem is useful for treating supraventricular tachycardia and atrial fibrillation with rapid ventricular response. In addition, calcium channel blockers cause vasodilation and can reduce blood pressure. <link document="m00313">Antihypertensive and Antianginal Drugs</link> discusses the use of calcium channel blockers in hypertension.</para>
<section id="sect-00025">
<title>Adverse Effects and Contraindications</title>
<para id="para-00073">Diltiazem can cause asystole; atrial flutter; first-, second-, and third-degree atrioventricular block; bradycardia; chest pain; congestive heart failure; sinus pause; sinus node dysfunction; syncope; ventricular dysrhythmia; ventricular fibrillation; ventricular tachycardia; dizziness; allergic reaction; Stevens–Johnson syndrome; and angioedema. It is important to note that the benefit of diltiazem in a life-threatening event outweighs the risk of adverse effects.</para>
<para id="para-00074">Contraindications include sick sinus syndrome, unless the client has a pacemaker; second- or third-degree heart block, unless the client has a pacemaker; severe hypotension and/or cardiogenic shock; hypersensitivity; ventricular tachycardia; and AMI.</para>
<para id="para-00075">Diltiazem should not be administered concurrently with IV beta-adrenergic blockers.</para>
<para id="para-00076"><link target-id="table-00007" document="m00389"/> is a drug prototype table for diltiazem use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00007">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Class</emphasis></span><newline/>
Nondihydropyridine calcium channel blocker; class IV antiarrhythmic drug<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Mechanism of Action</emphasis></span><newline/>
Inhibits calcium ions from entering the cell, resulting in decreased force of cardiac contraction and vascular smooth muscle relaxation</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Dosage</emphasis></span><newline/>
<emphasis effect="italics">For paroxysmal supraventricular tachycardia or atrial fibrillation with rapid ventricular response:</emphasis> 0.25 mg/kg actual body weight IV bolus over 2 minutes. If response inadequate, 0.35 mg/kg actual body weight IV bolus administered over 2 minutes. Subsequent bolus doses may be administered as needed according to the health care provider’s discretion.<newline count="2"/>
After initial bolus(es), continuous IV infusion may be needed, starting at 10 mg/hour for up to 24 hours.</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Indications</emphasis></span><newline/>
Atrial fibrillation with rapid ventricular response <newline/>
Supraventricular tachycardia<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Therapeutic Effects</emphasis></span><newline/>
Slows heart rate <newline/>
Lowers blood pressure</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Interactions</emphasis></span><newline/>
Beta-adrenergic blockers may increase incidence of bradycardia<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Food Interactions</emphasis></span><newline/>
Alcohol</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Adverse Effects</emphasis></span><newline/>
Allergic reaction<newline/>
Angioedema <newline/>
Asystole <newline/>
Atrial flutter<newline/>
First-degree atrioventricular block<newline/>
Second-degree atrioventricular block<newline/>
Third-degree atrioventricular block<newline/>
Bradycardia<newline/>
Chest pain<newline/>
Congestive heart failure<newline/>
Hypotension<newline/>
Sinus pause<newline/>
Sinus node dysfunction<newline/>
Syncope<newline/>
Ventricular dysrhythmia<newline/>
Ventricular fibrillation<newline/>
Ventricular tachycardia<newline/>
Dizziness<newline/>
Stevens–Johnson syndrome</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Contraindications</emphasis></span><newline/>
Sick sinus syndrome (unless client has pacemaker)<newline/>
Second- or third-degree heart block (unless client has pacemaker)<newline/>
Severe hypotension and/or cardiogenic shock<newline/>
Hypersensitivity<newline/>
Ventricular tachycardia<newline/>
Acute myocardial infarction</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Diltiazem</emphasis> (sources: https://dailymed.nlm.nih.gov/dailymed/; Talreja &amp; Cassagnol, 2022)</caption>
</table>
</section>
<section id="sect-00026">
<title>Nursing Implications</title>
<para id="para-00077">The nurse should do the following for clients receiving diltiazem intravenously:</para>
<list list-type="bulleted" id="list-00019">
<item>Place the client on continuous cardiac monitoring.</item>
<item>Monitor blood pressure frequently.</item>
<item>Monitor level of consciousness.</item>
<item>Have resuscitative equipment and drugs available.</item>
<item>Provide client teaching regarding the drug. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00014">
  <para id="para-00020">In supraventricular tachycardia or atrial fibrillation with rapid ventricular response, the client may not be conscious because of decreased cardiac output.</para>
<para id="para-00079"><emphasis effect="bold">If alert and oriented, the client receiving diltiazem should:</emphasis></para>
<list list-type="bulleted" id="list-00020">
<item>Inform the health care team if they have a known heart block or sick sinus syndrome.</item>
</list>
<para id="para-00080">See <link document="m00312">Antidysrhythmic Drugs</link> for client teaching guidelines for diltiazem in less acute situations.</para>
</note>
</section>
</section>
<section id="sect-00027">
<title>Epinephrine</title>
<para id="para-00081"><term class="no-emphasis" id="term-00031">Epinephrine</term> (<term class="no-emphasis" id="term-00032">adrenaline</term>) is a hormone that stimulates the SNS during the fight-or-flight response. SNS stimulation results in a faster heart rate, increased cardiac output, and pulmonary dilation (for increased oxygen intake), among other things. Epinephrine is a nonselective <term id="term-00033">adrenergic agonist</term>, which means it stimulates all receptors in the SNS. Epinephrine is used in a variety of emergency situations. In cardiac emergencies, epinephrine is used in ventricular fibrillation, pulseless ventricular tachycardia, asystole, and pulseless electrical activity.</para>
<section id="sect-00028">
<title>Adverse Effects and Contraindications</title>
<para id="para-00082">Epinephrine can cause anxiety and excitability, headache, fear, heart palpitations, tachycardia, supraventricular tachycardia, ventricular arrhythmias, hypertension, cerebral hemorrhage, hemiplegia, subarachnoid hemorrhage, anginal pain in clients with angina, pulmonary edema, hypoglycemia, hypokalemia, and lactic acidosis. It is important to note that the benefit of epinephrine in a life-threatening event outweighs the risk of adverse effects.</para>
<para id="para-00083">Contraindications to epinephrine include cardiac dilation, coronary artery insufficiency, and shock during general anesthesia. Epinephrine contains sodium bisulfate, which may cause an allergic reaction.</para>
<para id="para-00084"><link target-id="table-00008" document="m00389"/> is a drug prototype table for epinephrine use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00008">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Class</emphasis></span><newline/>
Adrenergic agonist (nonselective)<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Mechanism of Action</emphasis></span><newline/>
Binds to sympathetic nervous system receptors and stimulates the sympathetic nervous system, which causes increased heart rate, increased blood pressure, and increased oxygen intake in the lungs</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Dosage</emphasis></span><newline/>
<emphasis effect="italics">For ventricular fibrillation, pulseless ventricular tachycardia, asystole, and pulseless electrical activity:</emphasis> 0.1–1 mg IV bolus (using 0.1 mg/mL concentration) repeated every 5 minutes as necessary during cardiac resuscitation.<newline count="1"/>
<emphasis effect="italics">For anaphylaxis:</emphasis> 0.3–0.5 mg intramuscularly (using 1 mg/mL concentration), repeated every 5–10 minutes as needed.</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Indications</emphasis></span><newline/>
Emergency treatment of type I hypersensitivity reactions (anaphylaxis), ventricular fibrillation, pulseless ventricular tachycardia, asystole, and pulseless electrical activity<newline/>
Emergency treatment of anaphylaxis<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Therapeutic Effects</emphasis></span><newline/>
Increases heart rate<newline/>
Increases blood pressure<newline/>
Bronchodilation</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Interactions</emphasis></span><newline/>
Other sympathomimetic (adrenergic stimulant) drugs such as isoproterenol <newline/>
Digoxin <newline/>
Other medications may potentiate the effects:<newline/>
<list list-type="bulleted" id="list-00021">
<item>Tricyclic antidepressants</item>
<item>Antihistamines</item>
<item>Sodium l-thyroxine</item>
<item>Beta-adrenergic blockers</item>
</list>
Rapidly acting nitrates or alpha-blocking agents (may counteract epinephrine’s effects) <newline/>
Use with caution in clients taking monoamine oxidase inhibitors<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Food Interactions</emphasis></span><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Adverse Effects</emphasis></span><newline/>
Anxiety <newline/>
Excitability<newline/>
Headache<newline/>
Fear<newline/>
Heart palpitations<newline/>
Tachycardia <newline/>
Supraventricular tachycardia<newline/>
Ventricular arrhythmias<newline/>
Myocardial ischemia<newline/>
Hypertension<newline/>
Cerebral hemorrhage<newline/>
Hemiplegia<newline/>
Subarachnoid hemorrhage<newline/>
Anginal pain in clients with angina<newline/>
Pulmonary edema<newline/>
Hypoglycemia<newline/>
Hypokalemia<newline/>
Lactic acidosis</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Contraindications</emphasis></span><newline/>
Cardiac dilation<newline/>
Coronary artery insufficiency<newline/>
Shock during general anesthesia</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Epinephrine</emphasis> (sources: https://dailymed.nlm.nih.gov/dailymed/; Dalal &amp; Grujic, 2022; McLendon &amp; Sternard, 2022; Smith &amp; Maani, 2022)</caption>
</table>
</section>
<section id="sect-00029">
<title>Nursing Implications</title>
<para id="para-00085">The nurse should do the following for clients receiving epinephrine intravenously:</para>
<list list-type="bulleted" id="list-00022">
<item>Place the client on continuous cardiac monitoring.</item>
<item>Monitor blood pressure frequently. (Often, blood pressure is measured continuously when client is in shock.)</item>
<item>Monitor level of consciousness.</item>
<item>Have resuscitative equipment and drugs available.</item>
<item>Provide client teaching regarding the drug. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00015">
<para id="para-00086">In ventricular fibrillation, pulseless ventricular tachycardia, asystole, or pulseless electrical activity, the client will be unconscious. In anaphylaxis, the client may be unconscious.</para>
<para id="para-00087"><emphasis effect="bold">If alert and oriented, the client receiving epinephrine should:</emphasis></para>
<list list-type="bulleted" id="list-00023">
<item>Inform the health care team if they have a change in status (better or worse) after medication administration.</item>
<item>Inform the health care team if they notice a change in their breathing.</item>
</list>
</note>
</section>
</section>
<section id="sect-00030">
<title>Lidocaine</title>
<para id="para-00088"><term class="no-emphasis" id="term-00034">Lidocaine</term> is classified as a local anesthetic agent, but it is also a class Ib antiarrhythmic drug used in acute ventricular dysrhythmias. Lidocaine blocks sodium channels, which slows the cardiac action potential and causes the electrical stimulation threshold to be higher. The higher stimulation threshold causes the cardiac conduction cells to be less likely to conduct action potentials, which ultimately treats ventricular tachyarrhythmias.</para>
<section id="sect-00031">
<title>Adverse Effects and Contraindications</title>
<para id="para-00089">Lidocaine can cause respiratory depression and arrest, unconsciousness, convulsions, tremors, twitching, vomiting, blurred or double vision, drowsiness, dizziness, light-headedness, agitation, confusion, paresthesia, and dysarthria. It is important to note that the benefit of lidocaine in a life-threatening event outweighs the risk of adverse effects.</para>
<para id="para-00090">Contraindications to lidocaine include a history of hypersensitivity, Stokes–Adams syndrome, Wolff–Parkinson–White syndrome, and heart block.</para>
<para id="para-00091"><link target-id="table-00009" document="m00389"/> is a drug prototype table for lidocaine use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications. Lidocaine as a topical anesthetic is not addressed in this section.</para>
<table class="vertically-tight" id="table-00009">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Class</emphasis></span><newline/>
Class Ib antiarrhythmic<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Mechanism of Action</emphasis></span><newline/>
Blocks sodium channels in cardiac conducting cells, which ultimately causes slowed conduction and decreased heart rate</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Dosage</emphasis></span><newline/>
<emphasis effect="italics">For ventricular arrhythmias:</emphasis> 1–1.5 mg/kg IV bolus at 25–50 mg/min. Continuous IV infusion may be needed; usual dosing is 1–4 mg/min.</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Indications</emphasis></span><newline/>
Emergency management of ventricular arrhythmias<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Therapeutic Effects</emphasis></span><newline/>
Decreases heart rate</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Interactions</emphasis></span><newline/>
Other antiarrhythmic drugs (cardiac effects may be additive or antagonistic, which may lead to toxic effects)<newline/>
Propranolol, metoprolol, nadolol (increase the serum concentration of lidocaine)<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Food Interactions</emphasis></span><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Adverse Effects</emphasis></span><newline/>
Respiratory depression<newline/>
Respiratory arrest<newline/>
Unconsciousness<newline/>
Convulsions<newline/>
Tremors<newline/>
Twitching<newline/>
Vomiting<newline/>
Blurred or double vision<newline/>
Drowsiness<newline/>
Dizziness<newline/>
Light-headedness<newline/>
Agitation<newline/>
Confusion<newline/>
Cardiovascular arrest<newline/>
Bradycardia, which may lead to cardiovascular arrest<newline/>
Hypotension<newline/>
Ventricular fibrillation<newline/>
Ventricular tachycardia<newline/>
Asystole<newline/>
Allergic reaction, including anaphylaxis</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Contraindications</emphasis></span><newline/>
History of known reaction <newline/>
Stokes<emphasis effect="bold">–</emphasis>Adams syndrome<newline/>
Wolff<emphasis effect="bold">–</emphasis>Parkinson<emphasis effect="bold">–</emphasis>White syndrome<newline/>
Severe sinoatrial heart block<newline/>
Severe atrioventricular heart block<newline/>
Severe intraventricular heart block</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Lidocaine</emphasis> (sources: https://dailymed.nlm.nih.gov/dailymed/; Al-Khatib et al., 2018; Beecham et al., 2022; Klabunde, 2022)</caption>
</table>
</section>
<section id="sect-00032">
<title>Nursing Implications</title>
<para id="para-00092">The nurse should do the following for clients receiving lidocaine intravenously:</para>
<list list-type="bulleted" id="list-00024">
<item>Place the client on continuous cardiac monitoring.</item>
<item>Monitor blood pressure frequently.</item>
<item>Monitor level of consciousness.</item>
<item>Have resuscitative equipment and drugs available.</item>
<item>For continuous IV lidocaine infusion, closely monitor the rate and provide continuous ECG monitoring.</item>
<item>Monitor for adverse effects of lidocaine infusion</item>
<item>Provide client teaching regarding the drug. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00016">
<para id="para-00093"><emphasis effect="bold">The client receiving lidocaine should:</emphasis></para>
<list list-type="bulleted" id="list-00025">
<item>Inform the health care provider of tremors, twitching, nausea, vomiting, blurred or double vision, dizziness, lightheadedness, or confusion.</item>
</list>
</note>
<para id="para-00094">In acute ventricular arrhythmias, clients are typically no longer conscious. See <link document="m00312">Antidysrhythmic Drugs</link> for client teaching guidelines for lidocaine in less acute situations.</para>
</section>
</section>
<section id="sect-00033">
<title>Procainamide</title>
<para id="para-00095"><term class="no-emphasis" id="term-00035">Procainamide</term> is a <term class="no-emphasis" id="term-00036">class Ia antiarrhythmic</term> drug that binds to sodium channels, reducing the speed of conduction. It is used in life-threatening ventricular arrhythmias.</para>
<section id="sect-00034">
<title>Adverse Effects and Contraindications</title>
<para id="para-00096">Procainamide can cause hypotension, asystole, ventricular fibrillation, lupus erythematosus–like syndrome, pleural effusions, pericarditis, neutropenia, thrombocytopenia, hemolytic anemia, agranulocytosis, dizziness, weakness, and elevated liver enzyme levels.</para>
<para id="para-00097">Prolonged use of procainamide often leads to a positive antinuclear antibody (ANA) test; if this occurs, the risk–benefit ratio of procainamide use should be reassessed. It is important to note that the benefit of procainamide in a life-threatening event generally outweighs the risk of adverse effects.</para>
<para id="para-00098">Contraindications to the use of procainamide include a history of hypersensitivity, complete heart block, atrial fibrillation or flutter, congestive heart failure, lupus erythematosus, torsade de pointes, myasthenia gravis, and sulfite sensitivity.</para>
<para id="para-00099"><link target-id="table-00010" document="m00389"/> is a drug prototype table for procainamide use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00010">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Class</emphasis></span><newline/>
Class Ia antiarrhythmic<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Mechanism of Action</emphasis></span><newline/>
Antagonizes cardiac cell sodium channels, which ultimately slows the heart rate</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Dosage</emphasis></span><newline/>
<emphasis effect="italics">For life-threatening ventricular arrhythmias:</emphasis> Loading dose 10–17 mg/kg at a rate of 20–50 mg/min. Maintenance therapy may be indicated; dosing is variable.</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Indications</emphasis></span><newline/>
Emergency management of ventricular arrhythmias<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Therapeutic Effects</emphasis></span><newline/>
Decreases heart rate</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Interactions</emphasis></span><newline/>
Digitalis derivatives <newline/>
Other class Ia antiarrhythmic drugs<newline/>
Other antiarrhythmic drugs (may prolong the QT interval)<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Food Interactions</emphasis></span><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Adverse Effects</emphasis></span><newline/>
Hypotension <newline/>
Asystole <newline/>
Ventricular fibrillation <newline/>
Lupus erythematosus–like syndrome<newline/>
Pleural effusion <newline/>
Pericarditis <newline/>
Neutropenia <newline/>
Thrombocytopenia <newline/>
Hemolytic anemia<newline/>
Agranulocytosis <newline/>
Dizziness<newline/>
Weakness<newline/>
Elevated liver enzyme levels</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Contraindications</emphasis></span><newline/>
History of hypersensitivity<newline/>
Complete heart block<newline/>
Atrial fibrillation or flutter<newline/>
Congestive heart failure<newline/>
Lupus erythematosus<newline/>
Torsade de pointes<newline/>
Myasthenia gravis<newline/>
Sulfite sensitivity</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Procainamide</emphasis> (sources: https://dailymed.nlm.nih.gov/dailymed/; Pritchard &amp; Thompson, 2023)</caption>
</table>
</section>
<section id="sect-00035">
<title>Nursing Implications</title>
<para id="para-00100">The nurse should do the following for clients receiving procainamide intravenously:</para>
<list list-type="bulleted" id="list-00026">
<item>Place the client on continuous cardiac monitoring.</item>
<item>Monitor blood pressure frequently.</item>
<item>Monitor level of consciousness.</item>
<item>Have other resuscitative equipment and drugs available.</item>
<item>Monitor laboratory values, including ANA titer and liver enzyme levels, and report abnormal results to the health care provider</item>
<item>Provide client teaching regarding the drug. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00017">
<para id="para-00101"><emphasis effect="bold">The client receiving procainamide should:</emphasis></para>
<list list-type="bulleted" id="list-00027">
<item>Inform the health care provider of generalized rheumatic pain, dizziness, or weakness.</item>
</list>
</note>
<para id="para-00102">In acute ventricular arrhythmias, clients are typically no longer conscious. See <link document="m00312">Antidysrhythmic Drugs</link> for client teaching guidelines for procainamide in less acute situations.</para>
<note class="black-box" id="note-00018">
<para id="para-00103"><emphasis effect="bold">Procainamide</emphasis></para>
<para id="para-00104">Prolonged administration of procainamide often leads to the development of a positive antinuclear antibody (ANA) test, with or without symptoms of a lupus erythematosus–like syndrome. If a positive ANA titer develops, the benefit versus risks of continued procainamide therapy should be assessed.</para>
</note>
</section>
</section>
<section id="sect-00036">
<title>Dopamine and Dobutamine</title>
<para id="para-00105">After a cardiac event, clients often may still have hypotension or be in shock even after the immediate emergency is over. They may need medications to stabilize their blood pressure so that tissues are perfused. Dopamine and dobutamine are two drugs that help achieve and maintain hemodynamic stability.</para>
<section id="sect-00037">
<title>Dopamine</title>
<para id="para-00106">Endogenous (naturally occurring in the body) dopamine is a hormone that plays a role in stimulating the SNS. <term class="no-emphasis" id="term-00037">Dopamine</term>, an <term id="term-00038">inotropic agent</term>, is converted into epinephrine within the bloodstream. Dopamine binds to alpha-1, alpha-2, beta-1, and dopaminergic receptors. Adrenergic stimulation of alpha-1 and alpha-2 receptors causes vasoconstriction, which leads to increased blood pressure. Adrenergic stimulation of beta-1 receptors directly increases the heart rate.</para>
<para id="para-00107">Exogenous (synthetic) dopamine mimics the body’s own dopamine to the same effect. Dopamine is used in profound hypotension and shock to increase cardiac output by increasing the rate and force of contraction and blood pressure by vasoconstriction. At low doses (0.5–2 mcg/kg/min), dopamine causes vasodilation and can be used to increase urinary output. At intermediate doses (2–10 mcg/kg/min), it increases heart rate and stroke volume, which leads to increased cardiac output. At high doses, dopamine causes vasoconstriction, which increases blood pressure.</para>
<section id="sect-00038">
<title>Adverse Effects and Contraindications</title>
<para id="para-00108">Dopamine can cause ventricular arrhythmia, atrial fibrillation, ectopic beats, tachycardia, anginal pain, palpitations, cardiac conduction abnormalities, widened QRS complex, bradycardia, hypotension, hypertension, vasoconstriction, dyspnea, azotemia, headache, and anxiety. Extravasation of dopamine into the tissue around an IV site may cause necrosis, sloughing, and potentially gangrene. It is important to note that the benefit of dopamine in a life-threatening event outweighs the risk of adverse effects.</para>
<para id="para-00109">Contraindications to the use of dopamine include pheochromocytoma, uncorrected tachyarrhythmias or ventricular fibrillation, and allergy to metabisulfite.</para>
<note class="safety-alert" id="note-00019">
<title>Dopamine</title>
<para id="para-00111">Dopamine may cause peripheral ischemia in clients with a history of occlusive vascular disease.</para>
<para id="para-00112">Dopamine is a potent drug. It should be administered only in an intensive care area with proper monitoring available.</para>
</note>
<para id="para-00113"><link target-id="table-00011" document="m00389"/> is a drug prototype table for dopamine use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00011">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Class</emphasis></span><newline/>
<term class="no-emphasis" id="term-00039">Inotrope</term><newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Mechanism of Action</emphasis></span><newline/>
Converts to epinephrine in the bloodstream, which ultimately causes vasoconstriction and increased rate and force of contraction</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Dosage</emphasis></span><newline/>
<emphasis effect="italics">For hemodynamic instability:</emphasis> Initiate titration at 2–5 mcg/kg/min and titrate as directed by health care provider. Titration parameters include blood pressure and signs of tissue perfusion (adequate urine output).</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Indications</emphasis></span><newline/>
Emergency management of hypotension and shock<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Therapeutic Effects</emphasis></span><newline/>
Increases heart rate</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Interactions</emphasis></span><newline/>
Monoamine oxidase inhibitors<newline/>
Tricyclic antidepressants<newline/>
Beta-adrenergic blockers (may antagonize the effects)<newline/>
Alpha-adrenergic blockers (may antagonize the effects) <newline/>
Haloperidol<newline/>
Cyclopropane or halogenated hydrocarbon anesthetics<newline/>
Other vasopressors and oxytocic drugs<newline/>
Phenytoin<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Food Interactions</emphasis></span><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Adverse Effects</emphasis></span><newline/>
Ventricular arrhythmia<newline/>
Atrial fibrillation<newline/>
Ectopic beats<newline/>
Tachycardia<newline/>
Anginal pain<newline/>
Palpitations<newline/>
Cardiac conduction abnormalities<newline/>
Widened QRS complex<newline/>
Bradycardia<newline/>
Hypotension<newline/>
Hypertension<newline/>
Vasoconstriction<newline/>
Dyspnea<newline/>
Azotemia<newline/>
Headache<newline/>
Anxiety</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Contraindications</emphasis></span><newline/>
Pheochromocytoma<newline/>
Uncorrected tachyarrhythmias or ventricular fibrillation<newline/>
Allergy to metabisulfite</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Dopamine</emphasis> (sources: https://dailymed.nlm.nih.gov/dailymed/; Sonne et al., 2023)</caption>
</table>
</section>
<section id="sect-00039">
<title>Nursing Implications</title>
<para id="para-00114">The nurse should do the following for clients receiving dopamine intravenously:</para>
<list list-type="bulleted" id="list-00028">
<item>Place the client on continuous cardiac monitoring.</item>
<item>Monitor blood pressure frequently.</item>
<item>Monitor level of consciousness.</item>
<item>Have resuscitative equipment and drugs available.</item>
<item>Monitor IV site for signs of extravasation.</item>
<item>Monitor for signs and symptoms of occlusive vascular disease.</item>
<item>Provide client teaching regarding the drug. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00020">
<para id="para-00115">In hypotension or shock, the client may be unconscious.</para>
<para id="para-00116"><emphasis effect="bold">If the client receiving dopamine is alert and oriented, the client should:</emphasis></para>
<list list-type="bulleted" id="list-00029">
<item>Inform the health care team if they have a change in status (better or worse) after medication administration.</item>
<item>Inform the heath care team if they have pain at the IV site.</item>
<item>Inform the health care team if they have a headache.</item>
</list>
</note>
<note class="black-box" id="note-00021">
<para id="para-00117"><emphasis effect="bold">Dopamine</emphasis></para>
<para id="para-00118">Dopamine may cause peripheral ischemia in clients with a history of occlusive vascular disease.</para>
</note>
</section>
</section>
<section id="sect-00040">
<title>Dobutamine</title>
<para id="para-00119"><term class="no-emphasis" id="term-00040">Dobutamine</term> is a <term class="no-emphasis" id="term-00041">beta-1 adrenergic agonist</term> that stimulates the heart to contract more forcefully and, to a lesser extent, faster. It is used for the cardiac decompensation that can occur immediately after a cardiac event.</para>
<section id="sect-00041">
<title>Adverse Effects and Contraindications</title>
<para id="para-00120">Dobutamine can cause increased heart rate, increased blood pressure, ventricular ectopic activity, hypotension, and IV site reaction. It is important to note that the benefit of dobutamine in a life-threatening event outweighs the risk of adverse effects.</para>
<para id="para-00121">Contraindications to the use of dobutamine include idiopathic hypertrophic subaortic stenosis and hypersensitivity to bisulfite. Use after AMI may be contraindicated because of increased contractility. Dobutamine may cause marked increase in blood pressure or heart rate. Hypovolemia must be corrected prior to initiating dobutamine.</para>
<note class="clinical-tip" id="note-00022">
<title>Dobutamine</title>
<para id="para-00123">Dobutamine should not be mixed with any other drug in the same solution because it is incompatible with many other drugs.</para>
</note>
<para id="para-00124"><link target-id="table-00012" document="m00389"/> is a drug prototype table for dobutamine. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00012">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Class</emphasis></span><newline/>
Inotrope<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Mechanism of Action</emphasis></span><newline/>
Directly stimulates beta-1 receptors in the heart, which increases contractility and heart rate</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Dosage</emphasis></span><newline/>
<emphasis effect="italics">For hemodynamic instability:</emphasis> Initiate titration at 0.5–1 mcg/kg/min; titrate based on client response, including blood pressure and urine output.</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Indications</emphasis></span><newline/>
Short-term inotropic support for cardiac decompensation<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Therapeutic Effects</emphasis></span><newline/>
Increases contractility <newline/>
Increases heart rate</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Interactions</emphasis></span><newline/>
Beta-adrenergic blockers (may reduce the effectiveness of dobutamine)<newline/>
Sodium bicarbonate<newline/>
Alkaline solutions<newline count="2"/>
<span class="blue-text"><emphasis effect="bold">Food Interactions</emphasis></span><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Adverse Effects</emphasis></span><newline/>
Increased heart rate<newline/>
Increased blood pressure<newline/>
Ventricular ectopic activity<newline/>
Hypotension<newline/>
IV site reaction</entry>
<entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Contraindications</emphasis></span><newline/>
Idiopathic hypertrophic subaortic stenosis<newline/>
Hypersensitivity to bisulfite</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Dobutamine</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00042">
<title>Nursing Implications</title>
<para id="para-00125">The nurse should do the following for clients receiving dobutamine intravenously:</para>
<list list-type="bulleted" id="list-00030">
<item>Place the client on continuous cardiac monitoring.</item>
<item>Monitor blood pressure frequently.</item>
<item>Monitor level of consciousness.</item>
<item>Have resuscitative equipment and drugs available.</item>
<item>Ensure that dobutamine is not mixed with any other drug in the same solution.</item>
<item>Provide client teaching regarding the drug. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00023">
<para id="para-00126"><emphasis effect="bold">The client receiving dobutamine should:</emphasis></para>
<list list-type="bulleted" id="list-00031">
<item>Inform the health care team if any of these occur:
<list list-type="bulleted" id="list-00032">
<item>They have a change in status (better or worse) after medication administration.</item>
<item>They notice chest pain; dyspnea; or numbness, tingling, or burning in their extremities.</item>
<item>They have discomfort or pain at the IV site.</item>
</list></item></list>
</note>
</section>
</section>
</section>
<section id="sect-00043">
<title>General Nursing Implications for Cardiac Emergencies and Anaphylaxis</title>
<para id="para-00127">In the emergency department and critical care unit, nurses are current in cardiopulmonary resuscitation (CPR), advanced cardiac life support (ACLS), advanced trauma life support (ATLS), and other emergency certifications. Many nurses undergo certified emergency nurse (CEN) or certified critical care nurse (CCRN) certification. Advanced training for cardiac and other emergencies is helpful in a fast-paced, stressful environment.</para>
<note class="single-casestudy" id="note-00024">
<para id="para-00128">Read the following clinical scenario to answer the questions that follow.</para>
<para id="para-00129">James Ryan is a 72-year-old client whose wife brought him to the emergency department because of chest pain and difficulty breathing. He said he was shoveling snow from the sidewalk when he started having pain in his left arm and chest. He also had difficulty catching his breath. After a few minutes, James went inside and sat down, but the pain in his arm and chest continued. He started to feel lightheaded, and even though he was sitting down, he still found it hard to breathe. James wanted to lie down on the couch, but his wife insisted that he go to the emergency department.<newline count="2"/>
<emphasis effect="bold">History</emphasis><newline/>
Hypertension<newline count="2"/>
<emphasis effect="bold">Current Medications</emphasis> <newline/>
Losartan 50 mg daily<newline/>
Hydrochlorothiazide 25 mg daily</para>
<table class="vertically-tight full-width" id="table-00013">
<tgroup cols="3">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<colspec colnum="3" colname="c3" colwidth="3*"/>
<thead>
<row>
<entry valign="top" align="center" namest="c1" nameend="c2"><span class="blue-text"><emphasis effect="bold">Vital Signs</emphasis></span></entry>
<entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Physical Examination</span></emphasis></entry>
</row>
</thead>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="italics">Temperature:</emphasis></entry>
<entry valign="top" align="left">98.1°F</entry>
<entry valign="top" align="left" morerows="6"><list list-type="bulleted" id="list-00033"><item><emphasis effect="italics">Head, eyes, ears, nose, throat (HEENT):</emphasis> Within defined limits</item>
<item><emphasis effect="italics">Neurologic:</emphasis> Within defined limits</item>
<item><emphasis effect="italics">Cardiovascular:</emphasis> No jugular venous distension; S1 and S2 heard on heart auscultation; no S3 noted; brisk capillary refill in nailbeds of hands and feet</item>
<item><emphasis effect="italics">Respiratory:</emphasis> Clear to auscultation bilaterally</item>
<item><emphasis effect="italics">GI:</emphasis> Bowel sounds heard in all four quadrants, no tenderness, no distension</item>
<item><emphasis effect="italics">GU:</emphasis> Appropriate for age</item>
<item><emphasis effect="italics">Integumentary:</emphasis> Skin appropriate for age</item>
</list></entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="italics">Blood pressure:</emphasis></entry>
<entry valign="top" align="left">160/92 mm Hg</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="italics">Heart rate:</emphasis></entry>
<entry valign="top" align="left">86 beats/min</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="italics">Respiratory rate:</emphasis></entry>
<entry valign="top" align="left">20 breaths/min</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="italics">Oxygen saturation:</emphasis></entry>
<entry valign="top" align="left">96% on room air</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="italics">Height:</emphasis></entry>
<entry valign="top" align="left">5'11"</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="italics">Weight:</emphasis></entry>
<entry valign="top" align="left">240 lb</entry>
</row>
</tbody>
</tgroup>
</table>
<para id="para-00130">In the emergency department, James underwent an ECG and bloodwork, which revealed he was in the midst of an AMI.</para>
<exercise id="exer-00001"><problem id="prob-00001"><para id="para-00131"><link class="os-embed" url="#exercise/PHAR_Ch22_Sec02_UCSQ1"/></para></problem></exercise>
<exercise id="exer-00002"><problem id="prob-00002"><para id="para-00132"><link class="os-embed" url="#exercise/PHAR_Ch22_Sec02_UCSQ2"/></para></problem></exercise>
</note>
</section>
</section>
</content>
<glossary>
<definition id="def-00001"><term>adrenergic agonist</term> <meaning>a drug that stimulates adrenergic receptors, resulting in sympathetic nervous system stimulation</meaning></definition>
<definition id="def-00002"><term>anticholinergic</term> <meaning>having the effect of inhibiting the cholinergic receptors, which then inhibits the parasympathetic nervous system</meaning></definition>
<definition id="def-00003"><term>asystole</term> <meaning>a state of cardiac standstill; complete cessation of electrical activity of the heart</meaning></definition>
<definition id="def-00004"><term>atrial fibrillation with rapid ventricular response</term> <meaning>a dysrhythmia that involves rapid electrical stimulation, causing the atria and ventricles to contract rapidly</meaning></definition>
<definition id="def-00005"><term>calcium channel blocker</term> <meaning>a classification of drugs that prevent calcium from entering cells by binding to long-acting voltage-gated calcium channels in the heart, smooth muscle, and pancreas</meaning></definition>
<definition id="def-00006"><term>inotropic agent</term> <meaning>a drug that causes the heart to contract with more force</meaning></definition>
<definition id="def-00007"><term>nitrate</term> <meaning>a classification of drugs that cause vasodilation of blood vessels by imparting nitric oxide, which relaxes smooth muscles</meaning></definition>
<definition id="def-00008"><term>opioid agonist</term> <meaning>a drug that stimulates the opioid receptors and decreases pain sensations</meaning></definition>
<definition id="def-00009"><term>oxygen saturation</term> <meaning>measure of how much hemoglobin is bound to oxygen in the bloodstream</meaning></definition>
<definition id="def-00010"><term>pulseless electrical activity</term> <meaning>a life-threatening dysrhythmia in which the electrical system conducts impulses but the cardiac myocytes do not respond</meaning></definition>
<definition id="def-00011"><term>pulseless ventricular tachycardia</term> <meaning>a life-threatening dysrhythmia in which the ventricles contract so rapidly that a pulse cannot be detected</meaning></definition>
<definition id="def-00012"><term>supraventricular tachycardia</term> <meaning>rapid heart rate that originates above the ventricles</meaning></definition>
<definition id="def-00013"><term>symptomatic bradycardia</term> <meaning>heart rate less than 60 beats/min that causes the individual to have symptoms such as dizziness, lightheadedness, or fainting</meaning></definition>
<definition id="def-00014"><term>ventricular fibrillation</term> <meaning>a life-threatening dysrhythmia originating in the ventricles in which the ventricles are not coordinated in their contraction, leading to minimal cardiac output</meaning></definition>
<definition id="def-00015"><term>ventricular tachycardia</term> <meaning>a dysrhythmia that originates from the ventricles and causes them to contract rapidly</meaning></definition>
</glossary>
</document>